Basaglar Saved Medicaid Millions, Highlighting Benefits Of Competition, JAMA Analysis Shows
Executive Summary
Researchers analyzed usage rates, market share and reimbursement information for the long-acting insulins Lantus and Basaglar to determine the impact from the launch of Lilly’s long-acting Basaglar.